New light treatment could replace surgery for cervical precancer
NCT ID NCT07634497
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a light-activated drug (HAL-PDT) to treat cervical precancer (CIN2) in 500 women aged 18-50. The treatment is guided by how the cervix responds, with up to 4 sessions. The main goal is to see if the abnormal cells shrink or disappear within 6 months, avoiding the need for surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a blast of argon plasma wipe out cervical precancer without surgery?
- HPV DNA test could slash cervical cancer deaths in High-Risk populations
- Could a Light-Activated cream replace surgery for cervical precancer?
- New Same-Day test could transform cervical cancer screening in Low-Resource areas
- Can the HPV vaccine stop the virus in its tracks? new study aims to find out
- Keytruda may offer new hope for cervical precancer